Viewing nowCombinationDuvimet SR Tablets 0.5/100/1000 Milligrams
Metformin Hydrochloride 1000mg · Lobeglitazone Sulfate 0.5mg +1 more
Tablet · Prescription medication · Combination
JongKundang Co., Ltd.

MFDS item code 202301430 · Approved 2023.05.02 · Insurance code 643309330
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication helps improve blood sugar control in adult patients with type 2 diabetes by combining Rosiglitazone, Sitagliptin, and Metformin. It effectively supports blood sugar management when used alongside dietary and exercise therapy, thus improving the blood sugar control of patients.
For antidiabetic therapy, the recommended dose of this medicine is lobeglitazone sulfate 0.5 mg and sitagliptin 100 mg; the dose of extended-release metformin hydrochloride should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding 2000 mg. This medicine is generally administered once daily with the evening meal, and the dose is adjusted gradually to reduce gastrointestinal adverse reactions associated with metformin. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take 1 tablet of this medicine 0.5/100/1000 mg extended-release tablet once daily. Patients taking this medicine 0.25/50/500 mg, 0.25/50/750 mg, or 0.25/50/1000 mg extended-release tablets should take 2 tablets together once daily. If adequate glycemic control cannot be achieved with metformin and sitagliptin, the starting dose of this medicine should be lobeglitazone sulfate 0.5 mg, sitagliptin 100mg, and the dose of metformin hydrochloride currently being taken, or an appropriate dose therapeutically equivalent to it. For patients switching from combination therapy with lobeglitazone, sitagliptin, and metformin to this medicine, the dose of this medicine should be the existing dose of each component. No dose adjustment is necessary in patients with mild renal impairment [estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2], this medicine may be used by adjusting the metformin hydrochloride dose if it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis. Since the starting dose of extended-release metformin hydrochloride is 500mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or estimated glomerular filtration rate decreases to below 45ml/min or 45ml/min/1.73m2, respectively, administration of this medicine should be discontinued immediately.
This medication contains Rosiglitazone, which can place a strain on the heart, and should not be used in patients with heart failure or those showing symptoms of heart failure. Symptoms of heart failure include sudden weight gain, shortness of breath, and edema; if these occur, medical attention should be sought immediately. Additionally, the Sitagliptin component may rarely cause severe allergic reactions or acute pancreatitis, so patients experiencing symptoms such as skin rash or abdominal pain should visit a hospital immediately. The Metformin component may rarely cause a serious metabolic disorder known as lactic acidosis; thus, patients with impaired kidney function or liver disease should avoid this medication. If symptoms such as vomiting, diarrhea, abdominal pain, or fatigue occur, patients should consult a physician immediately. This medication should not be administered to patients with impaired kidney or liver function, heart failure, acute infections, or those scheduled for major surgery. If such conditions arise, the medication should be discontinued and healthcare professionals should be consulted. Regular blood tests and liver function tests should be conducted during treatment, and patients should notify their healthcare providers immediately if they experience sudden weight gain or symptoms such as edema and shortness of breath. Moreover, this medication carries a risk of hypoglycemia; therefore, patients should avoid skipping meals or engaging in excessive physical activity and should closely monitor blood sugar changes when used in combination with other diabetes medications. Women who are pregnant or planning to become pregnant must consult a physician, and premenopausal women should use appropriate contraceptive methods as ovulation may be stimulated. Lastly, excessive alcohol consumption should be avoided during the course of this medication, and if scheduled for a radiocontrast examination, drug use should be discontinued for a certain period before and after the test.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture and should be stored in a tightly closed container. It is best to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature. Proper storage preserves the effectiveness and safety of the medication for a longer duration.
Blue, oval-shaped, bi-convex, sustained-release film-coated tablet
Bottle packaging - 30 tablets/bottle, Bottle packaging - 6 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationMetformin Hydrochloride 1000mg · Lobeglitazone Sulfate 0.5mg +1 more
Tablet · Prescription medication · Combination
JongKundang Co., Ltd.
CombinationMetformin Hydrochloride 750mg · Lobeglitazone Sulfate 0.25mg +1 more
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Lobeglitazone Sulfate 0.25mg +1 more
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Lobeglitazone Sulfate 0.25mg +1 more
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.